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Pulmonary hypertension (PH) is the end result of a variety of diverse pathologic processes. The chronic elevation in pulmonary
artery pressure often leads to right ventricular pressure overload and subsequent right ventricular failure. In patients with left-
sided cardiac disease, PH is quite common and associated with increased morbidity and mortality. This article will review the
literature as it pertains to the epidemiology, pathogenesis, and diagnosis of PH related to aortic valve disease, mitral valve disease,
left ventricular systolic and diastolic dysfunction, and pulmonary veno-occlusive disease. Moreover, therapeutic strategies, which
focus on treating the underlying cardiac pathology will be discussed.
1.Introduction
Pulmonary hypertension (PH) occurs with an overall preva-
lence estimated at 15 per one million individuals [1]. It
is the end result of a variety of disparate pathophysiologic
processes. Ultimately, these disease states lead to a spectrum
of histopathologic lesions in the pulmonary vasculature with
diﬀering degrees of hypertrophy of the medial layer of the
vessel wall, hyperplasia of the intimal layer, proliferation
of the adventitial layer, and/or plexiform lesions [1]. These
changes in the structure of the pulmonary arterial vascular
bed lead to resistance to blood ﬂow, and correspondingly,
increased right ventricular (RV) pressures often leading to
RV pressure overload with eventual RV failure.
The most up-to-date classiﬁcation system categorizing
patientswith PHintogroupsbasedontheunderlyingdisease
process leading to PH was published in the European Society
of Cardiology Guidelines in 2009 (Table 1)[ 2]. Of these
groups, patients with Group 1PH, not including pulmonary
venoocclusive disease (PVOD), have been most extensively
studied in pharmacotherapy clinical trials. In addition, PH
is very common in patients with left-sided cardiac disease
and has been reported in greater than 60% of patients
with left ventricular systolic dysfunction, greater than 80%
of patients with left ventricular diastolic dysfunction, and
in 78% of patients prior to mitral valve surgery [3–6].
This article will review the current literature pertaining to
PH secondary to left-sided cardiac disease (Group 2PH),
includingPVOD(classiﬁedasGroup1  PH),pulmonaryvein
stenosis, mitral stenosis (MS), mitral regurgitation (MR),
aortic stenosis (AS), aortic regurgitation (AR), and left ven-
tricular systolic/diastolic dysfunction (Figure 1). In addition,
it is worth mentioning that a web membrane, between the
pulmonary veinsand the left atrial chamber, (cortriatriatum
sinister) and left ventricular inﬂow obstruction from a left
atrial myxoma have also been associated with pulmonary
hypertension. Other lesions that place a pressure overload
on the left ventricle (LV), such as systemic hypertension,
and the rare clinical entities of coarctation of the aorta, sup-
ravalvular aortic stenosis, and a subaortic membrane, have
been reported in association with PH. However,they will not
be discussed in detail individually.
2.Diagnosis
Consensus guidelines deﬁne pulmonary arterial hyperten-
sion (PAH) as a mean pulmonary artery (PA) pressure
greater than 25mmHg in the setting of a pulmonary capil-
lary wedge pressure (PCWP), left atrial (LA) pressure, or left
ventricularend-diastolicpressure(LVEDP)lessthanorequal
to 15mmHg [2]. Meanwhile, the term PH, in a less speciﬁc2 Pulmonary Medicine
Table 1: Classiﬁcation system of pulmonary hypertension into groups 1–5 based on underlying disease process.
Group 1 Group 1  Group 2 Group 3 Group 4 Group 5
(i) Idiopathic
(ii) Familial
(iii) Connective tissue diseases
(iv) Congenital shunt lesions
(v) HIV
(vi) Drugs/Toxins
(vii) Hemoglobinopathies
(viii) Portal hypertension
(ix) Persistent pulmonary
hypertension of the newborn
PVOD
(i) Left ventricular
systolic/diastolic
dysfunction
(ii) Left-sided
valvular dysfunction
Chronic lung
diseases and/or
hypoxemia
Chronic
thromboembolic
disease
Miscellaneous
(i) Sarcoid
(ii) Histiocytosis X
(iii) Fibrosing mediastinitis
(iv) Myeloproliferative
disorders
(v) Metabolic storage diseases
(vi) Thyroid disease
Right heart
Pulmonary arteries
Lung tissue
Pulmonary veins
Left atrium
Mitral valve
Left ventricle
Pulmonary veno-occlusive disease
Pulmonary vein stenosis
Cor triatriatum
Atrial myxoma
Mitral stenosis
Mitral regurgitation
LV diastolic dysfunction
Aortic valve disease
Figure 1: Anatomic organization of left heart causes of pulmonary hypertension from the right ventricle through the lungs to the left
ventricular outﬂow tract.
manner, refers to a mean PA pressure >25mmHg due to any
cause [2].
Transthoracic echocardiography is recommended as a
screening test in the evaluation of suspected PAH, and this
will provide essential information regarding concomitant
left-sided valvular or ventricular dysfunction [1]. In some
instances, however, invasive hemodynamic evaluation with
right heart catheterization is required to conﬁrm the diag-
nosis as echocardiography often underestimates the PA pres-
sures and does not provide an accurate assessment of PCWP
[1].
Careful analysis of the invasive hemodynamic data is
critical to making a correct diagnosis and recommending the
appropriatetherapeuticoptions.Aswillbediscussedindetail
infollowing sections, thevastmajority ofpatientswithPHin
the setting of an elevated PCWP should not be treated with
PAH vasodilator therapies. In order to ensure the accuracy
of the PCWP data, close attention should be given to the
ﬁdelity of the a-, c-, and v-wave morphologies on the PCWP
hemodynamic tracing. Furthermore, the PCWP should be
measured at end-expiration (intrapleural pressure is about
−5mmHg at that point). If there is any question about the
PCWP validity, then some advocate a PCWP wedge satura-
tion (it should be similar to pulmonary venous saturation if
done properly) and/or direct measurement ofthe LVEDPfor
conﬁrmation.
Vasodilator challenge is an integral element in the as-
sessment of suspected PAH and should be conducted forPulmonary Medicine 3
patients with a mean PA pressure ≥25mmHg and a PCWP
≤15mmHg. For patients with a PCWP >15mmHg, vasod-
ilator testing should generally not be performed, or if it is
performed, then it should be done with close hemodynamic
monitoring by experienced clinicians with expertise in the
evaluation of PAH due to the risk for development of acute
pulmonary edema and sudden respiratory compromise. Ap-
proximately 10% of patients with PAH have a positive re-
sponsetovasodilatorchallenge,deﬁnedasadecreaseinmean
PA pressure by >10mmHg to an absolute mean <40mmHg
without a decrease in systemic blood pressure or cardiac
output [2]. Inhaled nitric oxide, which has a very short
half-life (15–30 seconds), is most frequently used to assess
vasoreactivity [2, 7, 8]. Other agents including intravenous
nitroprusside, epoprostenol, and adenosine have also been
used for vasodilator response testing [2] .F o rp a t i e n t sw i t h
a cardiac shunt, nitroprusside should generally be avoided,
as this agent is also a potent arterial vasodilator that will
decrease systemic vascular resistance (SVR) and may facili-
tate right to left shunting leading to increasing hypoxemia.
3.Obstructionto PulmonaryVenousDrainage
Pulmonary venoocclusive disease (PVOD) is a rare entity
characterized by obliterative ﬁbrosis of small pulmonary
veins [9]. It is estimated that PVOD occurs with a prevalence
of 0.1-0.2 per one million in the population and is the cause
of 10% of the cases of PAH [9]. Signiﬁcant morbidity and
mortality is observed from PVOD-associated PAH with a
one-yearmortality of72%[10].Itscauseisunknownbuthas
been associated with viral infections and as a complication
of certain diseases such as scleroderma, systemic lupus
erythematosus, leukemia, chemotherapy, or bone marrow
transplantation.
Given the relative infrequency of PVOD in the popu-
lation, it is a challenging disease to characterize and study.
Small studies have suggested a statistical association between
PVOD among male gender and a history of smoking when
compared to a population of idiopathic PAH patients [11].
The clinical presentation of PVOD varies but often includes
dyspnea with exertion, hemoptysis, pulmonary edema, and
PAH. One clueis often the presence of segmental pulmonary
edema—something that should not occur with idiopathic
PAH. Otherwise, diﬀerentiating PAH due to PVOD from
othercausesbasedonclinicalandnoninvasiveevaluationcan
be challenging. One study reported statistically lower PaO2
and DLCO values in PVOD compared with idiopathic PAH
patients[11].However, theseare not speciﬁc ﬁndings unique
to PVOD. In the past, lung ventilation-perfusion scanning
was part of the diagnostic algorithm for the evaluation of
suspected PVOD, but this is no longer recommended due
to nonspeciﬁc ﬁndings and overlap with patterns of chronic
thromboembolic disease [9]. Right heart catheterization
demonstrates PAH but often with a lower mean PA systolic
and mean RA pressure than in patients with idiopathic PAH
[11]. The PCWP is often normal with a blunted waveform
but should be carefully measured in multiple, bilateral lung
zones as a notable diﬀerence in PCWP in one lung zone sug-
gests PVOD. Thus, if PVOD is suspected, it is crucial at right
heart catheterization that the PCWP be measured in both
upperand lowerlungﬁelds. Wedgeangiography canconﬁrm
the diagnosis (Figure 2). The wedge angiogram is performed
using a balloon-tipped catheter and hand-injecting contrast
media to ﬁll the distal pulmonary arterial bed. Release of the
balloon allows noncontrasted blood to wash out and opacify
the pulmonary venous system. By assessing the pulmonary
venous system in each quadrant, failure to visualize the re-
spective pulmonary vein in a quadrant is diagnostic of the
disease. Additionally, when PVOD is considered the likelyre-
spective, then vasodilator challenge with inhaled nitric oxide
should be avoided,orundertakenwith cautionand low-dose
administration, given multiple reports of severe pulmonary
edema developing after vasodilator challenge in PVOD pa-
tients [9]. Thus, the diagnosis of PVOD is made from a com-
bination of the above characteristics in the absence of left
ventricular diastolic dysfunction, left-sided valve dysfunc-
tion, or any other identiﬁable cause for PH.
Despite advances in the management of patients with
idiopathic PAH using vasodilator therapy, clinical improve-
ment has not been seen in PVOD-related PAH, and many
patientsactuallyclinicallydeterioratewiththeonsetofsevere
pulmonary edema after initiation of such agents due to the
obstruction in pulmonary venous outﬂow. Several recent
reports have suggested that epoprostenol may play a role in
bridging patients with PVOD to lung transplantation [9].
However, lung or heart-lung transplantation remains the
only eﬀective therapy, and patients should be referred to a
transplantation center upon diagnosis.
Finally, other obstructive lesions to pulmonary venous
drainage have been observed clinically and reported in the
literature infrequently. Pulmonary vein stenosis is one of
these lesions and can be either congenital or acquired. Ac-
quired pulmonary vein stenosis has been noted after elec-
trophysiologic ablation procedures and in patients with scle-
rosing mediastinitis. Also, cor triatriatum sinister and atrial
myxoma have the potential to impair pulmonary venous
drainage into the left atrium with the subsequent develop-
ment of PH.
4.Mitral Stenosisand Regurgitation
Elevation of PA pressures is commonly observed in patients
with both MS and MR. The presence or absence of PH
with mitral valve disease is a key element in the decision-
making algorithm for percutaneous or surgical intervention
on the mitral valve in the most recent American College
of Cardiology/American Heart Association Valvular Heart
Disease guidelines [12].
The mechanism by which PH develops in patients with
mitral valve disease is driven by an elevation of LA pressure,
which in turn, leads to pulmonary venous hypertension,
andsubsequently,pulmonary arterialhypertensiontodeliver
deoxygenated blood across the lungs from the right heart to
theleftheart.Leftatrialcomplianceisoftenreducedresulting
in an increased “v” wave in mitral valve disease. In patients
with MS, the elevation in LA pressure also results from4 Pulmonary Medicine
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Figure 2: Pulmonary vein wedge angiography. In panel (a) balloon occlusion with hand contrast injection demonstrates opaciﬁcation of
the distal branches of the right upper pulmonary artery (RUPA) and in panel (b) the levophaseof the wedge angiogram shows normalright
upper pulmonary vein (RUPV) drainage into the left atrium (LA). Panel (c) shows normal opaciﬁcation of the distal branches of the left
lower pulmonary artery (LLPA) with wedge angiography. However, during the levophase in panel (d), there is abnormaldrainage of the left
lower pulmonary vein (LLPV) with contrast persisting in the LLPA and the absence of contrast media in the LA diagnostic of PVOD.
the abnormal diastolic pressure gradient across the dysfunc-
tional mitral valve, while in patients with chronic MR, a
further increase in LA pressure results from the regurgitant
systolic jet and the rise in LV end-diastolic pressure.
With MS, there are two well-characterized associated
hemodynamic states. Initially, with progression of MS,
the mitral valve area (MVA) and cardiac output decrease
with a concomitant rise in the LA pressure [13]. Later in
disease progression, with a continued reduction in MVA and
elevationof LA pressures, changes in thepulmonary vascular
bed ensue, increasing the pulmonary vascular resistance
and PH. Often overt right heart failure occurs from right
ventricular (RV) pressure overload [13]. Thus, the early
stages of moderate to severe MS are associated with a decline
in cardiac output due to one lesion at the level of the mitral
valve.However,astheobstructiontoLVﬁllingbythestenotic
mitral valve worsens with the onset of PH, this “secondary
stenosis” at the pulmonary bed level may lead to both low
systemic cardiac output and RV failure.
Mitral stenosis, when moderate to severe, is associated
with a variable degree of PH in the majority of patients. The
pathophysiology of PH in MS involves structural alteration
of the pulmonary vascular bed mediated by the potent
vasoconstrictor endothelin-1 (ET-1) [14]. Levels of ET-1 are
three-fold higher in patients with severe MS compared with
healthy control subjects [14]. In a group of patients with
severe MS undergoing PBMV or mitral valve replacement
(MVR), the baseline ET-1 concentration is an independent
predictor of a decrease in PCWP at 6 months following
mitral valve intervention [14].
The American College of Cardiology (ACC)/American
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recommend intervention to relieve MS with percutaneous
balloon mitral valvuloplasty (PBMV) if the valve morphol-
ogy is favorable with a Wilkins score less than 8 and less
than moderate MR, or surgical MVR, when PH is present
[12]. More speciﬁcally, PBMV is advised for asymptomatic
patients with moderate or severe MS and a resting PA
systolic pressure greater than 50mmHg or a PA systolic
pressure greater than 60mmHg and/or a PCWP greater
than 25mmHg with exercise [12]. For patients with NYHA
class II-IV symptom status and moderate to severe MS,
PBMV is recommended if the criteria above are met [12].
If valve morphology is not amenable to PBMV or there is
also moderate to severe MR, then surgical valve replacement
should be pursued even if severe PH is present [12].
A large body of outcome data exists for PBMV in mitral
stenosis. Early work in the PBMV era showed that PA pres-
suresfell immediately afterPBMV,inconcertwith thereduc-
tion in mitral valve gradient [15] .I nt h ei m m e d i a t ep o s t -
procedure period, PVR declined in this study population
from 630 to 447dynes × sec/cm5 and subsequentlyexhibited
additional reduction to 280dynes × sec/cm5 at 7-month
follow-up catheterization [15, 16]. Further work in this area
conﬁrmed a reduction in PA pressures and PVR with PBMV
[17, 18]. Thus, one would expect relief of the MS by PBMV
to reduce PA pressures to normal or near-normal levels in
most patients. Following PBMV, surveillance for mitral valve
restenosis with the return of PH is necessary. Appropriately
selected patients with PH and MS should be referred to
tertiary care centerswith interventionalexperiencein PBMV.
Surgical correction with mitral valve repair or replace-
ment is the treatment of choice for chronic severe mitral
regurgitation. For patients with increased predicted periop-
erative morbidity and mortality, percutaneous intervention
with the MitraClip device may be considered. The most
recent ACC/AHA management guidelines endorse mitral
valve intervention if symptoms are present or in asymp-
tomatic patients with a left ventricular ejection fraction
(LVEF)lessthan 60%,a leftventricularend-systolic diameter
greater than 4cm, a resting PA systolic pressure greater than
50mmHg, or a PA systolic pressure greater than 60mmHg
with exercise [12].
Mostoftheclinicalstudiesevaluatingsurgeryforpatients
with mitral valve disease and PH included both MS and MR.
Thus, the surgical outcomesfor MS and MR will be reviewed
together. Without relief of mitral valve obstruction, observa-
tionaldatafromseveraldecadesagodemonstratedthatmean
survival was 2.4 years when severe PH was present with MS
[19]. Several small, observational studies initially reported
over forty years ago examined the changes in PA pressures
pre- and postoperatively with right heart catheterization
in patients with PH and mitral valve disease. One study
detailed the hemodynamic ﬁndings in 31 patients before
and at a mean of 7 months after Starr-Edwards prosthetic
MVR [20]. In this study, PA systolic pressures declined
from 75mmHg to 39mmHg with a concomitant increase
in the cardiac index from 2.04 to 2.99liters/minute/meter2
[20]. There was no diﬀerence in hemodynamic response
to surgery between those with MS and MR. Similar work
from the same era documented hemodynamic evaluation
from a preoperative baseline over the course of 8-9 days
postoperatively [21]. The mean PA pressures decreased from
71mmHg to35mmHg with an increase in the cardiac index
from 1.7 to 4.0liters/minute/meter2 from baseline values to
the end of the study period [21]. Another study from the
same time period evaluated 25 patients at rest and with
exercise to right heart catheterization preoperatively and at
one year following Starr-Edwards prosthetic MVR [22]. This
work reported a decline in PA pressures in 68% of patients
and an improvement in cardiac index in the majority of
patients one year after mitral valve surgery [22]. All patients
in the series demonstrated persistent exercise-induced PH,
which in most, was related to increased gradients across the
mitral valve during exercise [22].
Approximately 25 years after this original work, invasive
hemodynamic evaluation from 22 patients with rheumatic
mitral valve disease at preoperative baseline, and at 6 and
12 months following postoperative baseline was published
[23].This studydemonstrated asigniﬁcant diminution of PA
systolic pressures and PCWP at rest and with exercise from
baseline preoperative values to 6 months following surgery
[23]. Furthermore, from 6 to 12 months postoperatively,
there was an additional decrease in PA systolic pressures
during exercise [23].
Finally, the acute hemodynamic response to bileaﬂet
mechanical MVR was reported in 60 patients with PH
from the modern era [24]. This publication evaluated 30
patients with mild PH (mean PA pressure of 29mmHg)
and 30 patients with severe PH (mean PA pressure of
54mmHg) using invasive hemodynamic monitoring for 48
hours postoperatively [24]. In the cohort with mild PH,
the mean PA pressure fell to 16mmHg, while the cohort
with severe PH had a mean PA pressure of 23mmHg at 48
hours postoperatively [24]. Over 40 years of hemodynamic
research suggests that most patients have an improvement
in PA pressures to near-normal values following mitral
valve surgery with some patients exhibiting normal resting
pressures and persistent exercise-induced PH.
Patients with PH secondary to mitral valve disease have
been excluded from the clinical trials evaluating the cur-
rent United States Food and Drug Administration (FDA)-
approved PAH pharmacologic vasodilator therapies. Case
reports describing the safety and eﬃcacy of various vasodila-
tor agents during the immediate postoperative period in
patients undergoing mitral valve surgery with preoperative
PH have been published. The agents utilized include inhaled
prostacyclin, inhaled nitric oxide, intravenous nitroprusside,
and inhalediloprost,andthereportsfocused onacutehemo-
dynamic changes with the respective agents [25–29]. The
pharmacologic mechanisms of these agents target diﬀerent
cellular pathways. Inhaled iloprost and epoprostenol are
prostacyclin derivatives, which stimulate cyclic adenosine
monophosphate (cAMP) production leading to pulmonary
arterial smooth muscle relaxation [30]. In a similar manner,
milrinone, a type 3 cAMP phosphodiesterase inhibitor,
produces systemic and pulmonary arterial vasodilation by
blocking the metabolism of cAMP in smooth muscle cells
[31]. Through a diﬀerent pathway with stimulation of cyclic
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and nitroprusside inﬂuence pulmonary arterial smooth
muscle relaxation and vasodilation [30]. However, all of the
agents are associated with a decrease in mean PA pressure,
PVR, and with an increase in cardiac output. Moreover,
one publication reports a greater likelihood for separation
from cardiopulmonary bypass after mitral valve surgery in
patients with PH treated with inhaled iloprost compared
with no vasodilator therapy [29]. Pulmonary vasodilator
agents appear safe for short-term administration in patients
with PH during the perioperative mitral valvesurgery period
without any adverse events reported. Careful hemodynamic
monitoring of the PCWP is necessary during administration
to avoid the potential development of decompensated HF
and pulmonary edema.
In addition, there are isolated case reports detailing the
useofPAHpharmacotherapies as chronictherapy inpatients
with mitral valve disease and PH. The use of epoprostenol in
thismannerwasreportedinapatientwithresidualseverePH
after MVR. There was an improvement in functional status
and hemodynamics with a decrease in mean PA pressure and
an increase in cardiac output [32]. Likewise, the successful
use of the oral pulmonary vasodilator, sildenaﬁl, following
MVR in a patient with persistent severe PH has been noted
[33]. The future role, if any, that conventional PAH drug
therapy may play in the management of patients with PH
and mitral valve disease that persists after surgery, or in
patients who are not candidates for surgical or percutaneous
intervention, remains to be determined through rigorous
scientiﬁc evaluation.
5.AorticStenosis
Valvular AS is one of the most frequently encountered
pathologies in the practice of adult cardiovascular medicine.
However, the association of PH with severe AS is often
underappreciated and varies with the threshold used for
the detection of the presence of PH. Aortic stenosis results
in PH by creating LV diastolic dysfunction and subsequent
pulmonary venous hypertension due to associated LV hyper-
trophyandreducedLVdiastolicfunction. Oneoftheoriginal
systematic characterizations of PH in patients with severe AS
reported a prevalence for PH of 50% using the threshold of a
PA systolic pressure of >30mmHg [34]. In this publication,
PH was statistically associated with an elevated LVEDP [34].
Subsequently, using a cutoﬀ value of a PA systolic pressure
>50mmHg,29%ofpatientswithsevereAShadconcomitant
PH [35]. More recently, in a cohort of nearly 400 patients
with symptomatic severe AS, 50% had mild to moderate PH
withmeanPApressuresof31–50mmHgand15%hadsevere
PH with a mean PA pressure >50mmHg [36]. Of note, in
bothofthese studies,themajority ofpatientshad anelevated
transpulmonary gradient (TPG) suggesting that over time
changes in the pulmonary vasculature had occurred leading
to PH out-of-proportion to the PCWP/LVEDP.
Several echocardiographic studies have examined the
relationship between severe AS and PH. In a small study
involving 50 patients with severe AS and PH, multivariate
analysis revealed that diastolic function as assessed by E/e’
was the only independent predictor of PH [37]. However, in
a larger study involving 626 patients, multivariate analysis
showed that lower LVEF, severity of concomitant mitral
regurgitation, smaller aortic valve area, and not taking a
statin medication independently predicted PH [38]. These
data suggest that additional left-sided cardiac pathology in
addition to diastolic ﬁlling abnormalities may increase the
likelihood for developing PH in patients with severe AS.
Thus, careful hemodynamic evaluation is required to detect
the presence of PH and any associated lesions given the
increased surgical morbidity and mortality with aortic valve
replacement when PH is present.
Surgical aortic valve replacement (AVR) is the recom-
mended therapeutic intervention for patients with symp-
tomatic, severe AS with a mean gradient greater than
40mmHgoranaortic valvearea less than1.0cm2 [12].Like-
wise, AVR is advised in the asymptomatic patient when the
LVEF is less than 50% [12]. However, perioperative morbid-
ity and mortality increase signiﬁcantly when PH is present.
This is partly due to persistent pulmonary hypertension
immediately after AVR, since LV diastolic dysfunction im-
proves only after there is LV remodeling following AVR, and
this may take several months.
In onestudy, the characteristics of 47patients with severe
AS and severe PH during the time period of 1987 to 1999
were analyzed, and the outcome demonstrated that periop-
erative mortality was 16% [39]. For the group of patients
who had valve surgery and survived, PA pressures gradually
declined, with an improvement in New York Heart Associ-
ation (NYHA) class and LVEF [39]. The beneﬁt from AVR,
though, can be striking; a retrospective analysis of a cohort
of 116 patients with severe AS and severe PH showed a 30-
day mortality of 8% in patients who had AVR versus 30%
for those not having AVR [40]. This statistically signiﬁcant
survivaldiﬀerencepersistedwith34%mortalityinthosewho
underwent AVR and 80% mortality in those without valve
replacement at 5 year followup [40]. In addition, AVR was
associated with a survival beneﬁt after multivariate logistic
regression analysis to control for other variables of comor-
bidityandwiththeuseofapropensityscoreadjustment[40].
Based on analysis ofnonrandomized, observational data,
AVR in patients with severe PH and AS is associated with
increased perioperativemortalitycomparedtopatientswith-
outPH.However,AVRisalsoassociatedwithimprovedlong-
term survival and should be considered in selected patients
at experienced, high-volume surgical centers. Based on the
dramatic results of initial clinical trial data, transcatheter
aortic valve replacement will also likely be an option in the
future for patients with severe AS and PH who are at high
risk for surgical AVR due to other comorbid conditions. At
the present time, even isolated case reports on the use of
pulmonary vasodilators in patients with severe PH and AS
are lacking from the literature and the use of such agents
cannot be recommended.
6.AorticRegurgitation
Elevation of pulmonary artery pressures secondary to iso-
lated aortic valve regurgitation (AR) is less common thanPulmonary Medicine 7
with other valve lesions but does occur. Prior studies have
reported a prevalence of PH in 10–20% of patients with
severe AR [41]. The pathophysiology is explained by a
chronic elevation of the LVEDP, which in turn, leads to an
increase in LA and PA pressures or due to the acute elevation
in LVEDP with acute severe AR (such as what might be
observed in endocarditis or aortic dissection).
In chronic AR, surgery to replace the aortic valve is
indicated when there are symptoms present with severe AR
or with asymptomatic severe AR when the LVEF is less
than 50% or there is dilation of the LV [12]. Retrospective
analysis of 139 patients with PH and AR was reported nearly
twenty years ago. This work observed that there was no
signiﬁcant diﬀerence in operative mortality or postoperative
complications in patients undergoing AVR with severe PH
and severe AR compared with mild or no PH and severe
AR[42].Furthermore, PA pressures declined to near-normal
values in the vast majority of patients following AVR [42].
More recently, a single-center retrospective study of 506
patients with severe AR demonstrated that severe PH was
statistically associated with lower LVEF, greater LV end-
diastolic and end-systolic dimensions, and a higher grade
of concomitant MR [41]. Moreover, multivariate analysis
with propensity score adjustment showed an independent
association between AVR and survival in patients with both
severe PH and severe AR during 5 years of followup [41].
Although limited by potential selection bias, this work
suggests that AVR can be performed with acceptable peri-
operative risk in patients with severe PH due to AR. In
addition, it also highlights the recurrent theme that valve
surgery is often associated with a signiﬁcant improvement in
PA pressures and improved survival based on observational
datasets.
7.LeftVentricularDiastolic Dysfunction
AssociatedwithPreservedSystolic Left
VentricularFunction
Heart failure with preserved systolic function accounts for
over half of hospitalizations for congestive heart failure. This
category represents a varied group of disease states including
systemic hypertension, hypertrophic cardiomyopathy, inﬁl-
trative cardiomyopathies, Fabry’s disease, and obstructive
sleep apnea. Some of these patients will develop PH as a
response to the abnormal diastolic ﬁlling of the LV. Likewise,
thereisagrowingpopulationofelderlypatientswithdyspnea
who have PH in which HF with preserved LVEF appears to
be the most common cause [43]. The common link between
all of these pathologies is the impairment of diastolic ﬁlling.
Over time this leads to an increase in LA pressure in order to
adequately ﬁll the LV during diastole and a reduction in LA
compliance. Subsequently, with the increase in LA pressure,
there is a corresponding rise in PV and PA pressure. In some
patients with long-standing elevation of LA pressure, the
TPG gradient rises out of proportion to the LA pressure.
The epidemiology and association of PH in patients with
normal LV function and diastolic dysfunction have been well
recognized over the last decade. A recent population-based
study of 244 patients with HF and preserved LVEF observed
PH in 83% of patients as deﬁned by an echocardiographic
Doppler estimation of PA systolic pressure greater than
35mmHg [5]. Furthermore, PH in patients with HF and
preserved LV function has been found to be a strong predic-
tor of mortality during a 2.8-year follow-up period [5]. This
will likely be an increasing clinical problem in the coming
years with the aging population and the epidemic of diabetes
mellitus and obesity.
For the diagnosis of PH related to impaired diastolic
ﬁlling, other potential causes of PH must be excluded. Right
heart catheterization is obligatory and will usually reveal an
elevated PCWP and LVEDP, mean PA pressure, and in some
patients an elevated PVR with an exaggerated TPG gradient.
Although not part of the diagnostic criteria in the PH
guidelines, invasive hemodynamic evaluation with supine
bicycle or arm weight exercises may occasionally be useful to
better understand the symptomatic limitation of individual
patientswithsuspected PHduetodiastolic dysfunction [44].
At the present time, there are no guideline recommenda-
tions or clinical trial data regarding the management of PH
in diastolic HF [1]. General guidance on the management of
HF with preserved LV function has been published, however,
emphasizing the importance of control of systemic blood
pressure, rate control for atrial ﬁbrillation if present, and
diuretic usage if needed to avoid hypervolemia [45]. In the
future, results from the currently enrolling Evaluating the
Eﬀectiveness of Sildenaﬁl at Improving Health Outcomes
and Exercise Ability in People with Diastolic Heart Failure
(RELAX) trial may provide information on the use of
sildenaﬁl pulmonary vasodilator therapy in this speciﬁc
patient population [46].
8.LeftVentricularDiastolic
Dysfunction AssociatedwithLeft
VentricularSystolicDysfunction
Pulmonary hypertension is commonly found in patients
withleftventricularsystolicdysfunction.Ithasbeenreported
thattwo-thirdstothree-fourthsofpatientswithsystolicheart
failure(HF)duetoischemicornonischemiccardiomyopathy
haveassociated PH [31]. However,thepresence orseverityof
PH does not correlate with LVEF [47]. The greatest predic-
tors of PH in a population with LV systolic dysfunction are
the grade of MR and mitral inﬂow E-wave deceleration time
[48]. The latter reﬂects the rapid rise of LV diastolic pressure
and decline in ﬁlling when there is diastolic dysfunction.
Hence, the degree of LV systolic dysfunction is not the
primary characteristic responsible for the development of
PH, but rather the degree of LV diastolic ﬁlling impairment
and associated functional MR.
Greater understanding of the physiological mechanisms
of PH in HF with systolic dysfunction has evolved over the
last two decades. The circulating peptide ET-1 is a potent
vasoconstrictor and seems to play a role in the development
ofPHwithMR.ElevatedlevelsofcirculatingET-1inHFhave
been linked to higher PA pressures and PVR [49]. Moreover,
ET-1 concentration has a strong positive correlation with8 Pulmonary Medicine
NYHA class and a strong inverse relationship with LVEF
and cardiac index [50]. Thus, the ET-1 receptor represents
a logical therapeutic target.
Symptoms such as shortness of breath at rest and with
exertion are a major manifestation of systolic HF, which
negatively impact activity level and quality of life. In patients
with a reduced LVEF, the concomitant presence of PH corre-
lates with more advanced symptom status and greater func-
tional impairment as reﬂected by a statistically higherNYHA
class than a similar cohort with LV systolic dysfunction
without PH [3]. This eﬀect has been objectively documented
with cardiopulmonary exercise (CPX) testing. CPX testing
in 320 patients with an LVEF less than 40% demonstrated
that cardiac output and peak oxygen consumption with
exercise were signiﬁcantly lower in those with an elevated
PVR,further emphasizingtheassociationofPHonsymptom
status and hemodynamics.
When PH is present with systolic HF, it is also associated
with increased risk of death [51, 52]. One study which fol-
lowed 400 patients for 5 years estimated that there was a
9% increase in mortality for every 5mmHg increase in right
ventricular systolic pressure using Cox proportional hazards
statistical analysis to adjust for other variable known to
impact mortality [53]. Given the high mortality for patients
with HF due to LV systolic dysfunction at 5 years, the devel-
opment of PH, which appears to further increase the risk of
death, represents a serious problem.
SelectedpatientswithadvancedHFsymptomsandsevere
LV systolic dysfunction are often considered for orthotopic
heart transplantation. Multiple studies have examined the
impact of PH on outcomes in patients undergoing trans-
plant. The synthesis of the various studies shows that when a
PVR greater than 2.5 Wood units and a TPG gradient greater
than 15mmHg is present, there is an increase in mortality
at 3 month and 1 year posttransplant [47]. Mortality at
one year posttransplant was 5.6% with a PVR less than 2.5
Wood units and a TPG gradient less than 15mmHg, while
it was 24.4% in those with hemodynamics exceeding these
threshold values [54]. Thus, PH with a PVR greater than
5 Wood units is a relative contraindication to transplant
basedontheInternational SocietyforHeart and LungTrans-
plantation guidelines [55]. Moreover, vasodilator challenge
should be assessed during right heart catheterization to
evaluate whether the elevated PVR is ﬁxed or vasoreactive
[55]. Observational data has shown that there is a signiﬁcant
reduction in mortality at 3 month posttransplant in patients
with a pretransplant PVR >2.5 Wood units in whom
the PVR decreased <2.5 Wood units with nitroprusside
administration when compared to patients without such a
decline in PVR (3.8% versus 40.6%) [56]. In a recent small
pilot study, 6 pretransplant patients with a TPG gradient
greater than 12mmHg, a PVR greater than 2.5 Wood units,
and no reversibility with intravenous (IV) nitroprusside
were given sildenaﬁl for one month [57]. After one month
of treatment, three patients demonstrated a normalization
of TPG and PVR and 2 patients exhibited a decline in
PA pressures with IV nitroprusside [57]. It is anticipated
that future inquiry will expand our understanding of the
use of pulmonary vasodilator therapies in the pretransplant
population. Moreover, resolution or improvement in PH has
also been reported in patients who have had recovery of LV
function or who have undergone cardiac transplantation or
left ventricular assist device (LVAD) placement.
There appears to be an expanding role for the LVAD as
a bridge to heart transplant in the management of patients
with severe left ventricular systolic HF and PH. Several
studies in patients with systolic HF and severe PH have
demonstrated that an elevated PVR despite pharmacologic
therapy is often reduced to <2.5 Wood units over a 6 month
time period following LVAD placement [58–62]. Retrospec-
tive, observational data analysis has also established that in
patients in whom the pulmonary pressure improves with
LVAD therapy as bridge to transplant, there is no statistical
diﬀerence in subsequent posttransplant survival compared
to patients without PH [60, 61]. The beneﬁcial actions of
theLVADundoubtedlyrelate toafterload reductionoftheLV
and a reductioninthe PCWPwith corresponding reductions
in the mean PA pressure and PVR. Improvement in the PVR
hasbeenreportedwithbothpulsatileﬂowdevicesandnewer,
continuous ﬂow LVADs [63] .G i v e nt h es t r o n gc o r r e l a t i o no f
an elevated PVR and an adverse outcome following ortho-
topic heart transplant, the use of LVAD therapy to reduce
the PVR prior to transplant may improve the transplant
outcomes in these patients.
AlthoughtherearenoFDA-approvedagentsforthetreat-
ment of PH due to LV systolic dysfunction, the use of long-
term pulmonary vasodilator therapy has been attempted to
improvesymptoms.Early workinthisareawithchronicepo-
prostenol administration in the Flolan International Ran-
domized Survival trial (FIRST), however, observed an in-
creased mortality in the cohort with LV systolic dysfunction;
the trial was terminated early by the Data Safety Monitoring
board [64]. Subsequently, small series have investigated the
eﬃcacy and hemodynamic actions of other vasodilator ther-
apies in patients with systolic HF and PH. As described ear-
lier, endothelin-1 likely plays an important role in the patho-
physiology of PH in this setting. Therefore, drugs targeting
inhibition of the endothelin receptor have been developed
and are approved for chronic therapy in idiopathic PAH.
Unfortunately, long-term studies involving the endothelin
receptor antagonists, darusentan and bosentan, have not
shown any beneﬁcial actions on LV chamber size, or neu-
rohormonal levels with darusentan, or on symptoms with
bosentan [65, 66]. Another agent, nesiritide, a recombinant
version of human brain natriuretic peptide, has also been
extensively studied with mixed results. One of the hemody-
namic actionsofnesiritideistodecreasethePCWP,themean
PA pressure, and PVR acutely with short-term infusion [67].
Milrinone,aninhibitoroftype3phosphodiesterase,isan
inotrope and systemic vasodilator used in the management
of acute decompensated HF from LV systolic dysfunction. It
alsohas hemodynamicactions onthepulmonary vasculature
by decreasing PVR and augmenting RV function [68]. In
clinical practice, it is used in selected patients as a bridge
to transplant or in the perioperative period after LVAD
placement in patients with systolic HF and PH.Pulmonary Medicine 9
Finally, the type 5 phosphodiesterase inhibitor, sildenaﬁl,
which is approved for chronic therapy of idiopathic PAH,
has been evaluated in PH with systolic HF. During a 6
month randomized trial of sildenaﬁl or placebo in 46
patients with mild PH and systolic HF, there was statistically
signiﬁcant reduction in PA pressures and an increase in peak
oxygen consumption during CPX testing, without adverse
side eﬀects reported [69]. Similarly, the randomization of
34 patients to sildenaﬁl or placebo showed an improvement
in PVR, peak oxygen consumption during CPX testing, 6-
minute walk duration, and qualityof life with sildenaﬁl ther-
apy at 3 months [70]. Larger scale clinical trials with longer
followup are needed, though, to determine what role, if any,
sildenaﬁl will play in the management of PH in systolic HF.
The cornerstone of therapy for patients with PH and LV sys-
tolic dysfunction remains evidence-based HF therapies such
as beta-blockers, angiotensin-converting enzyme inhibitors,
and aldosterone antagonists, which reduce afterload on the
LV and inﬂuence favorable myocardial remodeling leading
to improved LV diastolic properties, and in turn, lower LA
pressure with a corresponding reduction in PA pressures.
9.Conclusion
In conclusion, PH frequently develops in response to left-
sidedcardiacdisease duetoelevatedpulmonary venouspres-
sure and is associated with a series of lesions that range from
diseases of the pulmonary veins, mechanical obstruction in
the LA or at the mitral valve, or to elevation in the left atrial
and pulmonary venous pressure due to mitral regurgitation,
abnormal LA compliance, or to LV diastolic dysfunction. In
some patients, secondary pulmonary hypertension appears
to occur in addition. Pulmonary hypertension is associated
with increased morbidity and mortality. In the setting of
PH-related to left-sided obstructive or regurgitant valve
disease, the PA pressures commonly decrease signiﬁcantly or
return to normal after valve replacement, repair, or mitral
valvuloplasty; unfortunately this does not occur in all.
For patients with left ventricular systolic/diastolic dys-
function, the prognosis and options for treatment of associ-
atedpulmonary hypertensionindependentoftherapyforthe
left heart disease are less favorable. Although not included
in the vast majority of PAH vasodilator therapy clinical
trials, vasodilator therapy may be of clinical beneﬁt in a few
carefully selected patients with left-sided cardiac disease in
whom PH does not improve after addressing the underlying
cardiac pathology.
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